We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Link Identified Between Mitochondria and Pancreatic Cancer Risk

By LabMedica International staff writers
Posted on 18 Oct 2022

Tumors invariably rewire their metabolism to promote cellular plasticity, adapt to ever-changing nutrient availability and acquire traits of aggressive disease, including metastatic competence. More...

Cancer metabolism has long been equated with the preferential utilization of glycolysis by tumor cells even when oxygen is present.

Although mechanisms of mitochondrial reprogramming in cancer have recently come into better focus, the role of organelle fitness in this process has not been widely considered. In fact, the microenvironment of tumor growth is highly unfavorable to mitochondria, as erratic oxygen concentrations and oxidative radicals can compromise organelle integrity, deregulate multiple mitochondrial functions, and activate cell death.

A multidisciplinary international team of scientist led by The Wistar Institute (Philadelphia, PA, USA) examined primary patient samples with histologically confirmed diagnosis of normal brain parenchyma (tumor-free surgical margins, N = 5), low grade gliomas (LGG, N = 4, oligodendroglioma, astrocytoma) and glioblastoma (GBM, N = 6) for differential expression of the Mic60-low gene signature by qPCR. Four μm-thick sections from tissue blocks of human pancreatic ductal adenocarcinoma (PDAC) tissue samples were stained with a primary antibody to Mic60 (BD Biosciences, San Jose, CA, USA) using Benchmark Ultra Roche Ventana Immunostainer (Roche Group, Tucson, AZ, USA) and diaminobenzidine (DAB) as a chromogen. All slides were counterstained with hematoxylin.

Human PDAC cell lines PANC-1 and CAPAN-2 were transfected with control non-targeting siRNA or Mic60-directed siRNA. Transfected PANC-1 and CAPAN-2 cells were harvested and RNA was immediately extracted. Reverse-transcription reaction performed on a Bio-Rad T100 Thermal Cycler (Bio-Rad Laboratories, Hercules, CA, USA). Quantitative PCR was performed with SYBR Select Master Mix on ABI Quant Studio 5 machine (Thermo Fisher Scientific, Waltham MA, USA). As discovery dataset, log2-transformed mRNA expression values were downloaded from 33 tumor samples in The Cancer Genome Atlas (TCGA) database of the UCSC Xena browser.

The investigators showed that showed that an 11-gene Mic60-low signature is associated with aggressive disease, local inflammation, treatment failure, and shortened survival, ultimately demonstrating the clinical relevance of protein. expression of the Mic60-low gene signature in the TCGA dataset of PDAC was associated with shortened overall survival (HR = 1.87, N = 176), disease-specific survival (HR = 1.73), Therefore, the Mic60-low gene signature may be used as a simple tool or biomarker to estimate cancer risk for PDAC and potentially other types of cancer, including glioblastoma.

Dario C. Altieri, MD, a Professor of Immunology and a senior author of the study, said, “To the best of our knowledge, this is the first time that a gene signature of mitochondrial dysfunction is linked to aggressive cancer subtypes, treatment resistance and, unfortunately low patient survival rates. Although our work has focused on the mitochondrial protein Mic60 in this response, we know that dysfunctional mitochondria are commonly generated during tumor growth, suggesting that this is a general trait in cancer.”

The authors concluded that based on their findings, the Mic60-low gene signature may provide an easily accessible, point-of-service molecular tool to stratify patient risk in PDAC and potentially other malignancies, including GBM. The study was published on October 12 2022 in the journal PLOS ONE.

Related Links:
The Wistar Institute
BD Biosciences
Roche Group
Bio-Rad Laboratories
Thermo Fisher Scientific 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.